Primary cutaneous B-cell lymphoma: classification and treatment.

Area of Science:

• Dermatology
• Hematology
• Oncology

Background:

• Primary cutaneous B-cell lymphomas (PCBCLs) have lacked clear definitions and treatment guidelines, leading to diagnostic and therapeutic confusion.
• Existing classifications and treatment approaches for PCBCLs have been inconsistent.
• The need for a standardized classification system is critical for effective patient management.

Purpose of the Study:

• To present the updated World Health Organization-European Organization for the Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas.
• To detail the clinicopathologic, immunophenotypic, and genetic characteristics of PCBCL subtypes within this new framework.
• To discuss current therapeutic strategies for different types of PCBCLs.

Main Methods:

• Review of existing literature and expert consensus on cutaneous lymphoma classification.
• Analysis of clinicopathologic, immunophenotypic, and genetic data for PCBCL subtypes.
• Synthesis of current treatment guidelines and evidence-based recommendations.

Main Results:

• The revised classification identifies three primary PCBCL types: primary cutaneous marginal zone B-cell lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous large B-cell lymphoma (leg type).
• Primary cutaneous marginal zone B-cell lymphoma and primary cutaneous follicle center lymphoma are characterized as indolent, with excellent prognoses and suitability for non-aggressive therapies.
• Primary cutaneous large B-cell lymphoma (leg type) is identified as an aggressive lymphoma requiring intensive chemotherapy.

Conclusions:

• The WHO-EORTC classification provides a standardized approach to diagnosing and managing PCBCLs.
• This classification will improve diagnostic consistency and prevent overtreatment of indolent PCBCL subtypes with systemic chemotherapy.
• Uniform diagnostic criteria and treatment strategies are expected to enhance patient outcomes.